Advertisement

Pharmaceutisch Weekblad

, Volume 14, Issue 3, pp 152–158 | Cite as

Single-dose tolerance and pharmacokinetics of 2-n-propyl-2(E)-pentenoate (Δ2(E)-valproate) in healthy male volunteers

  • R. H. Düsing
Recent Developments on Valproate and its Metabolites

Abstract

2-n-Propyl-2(E)-pentenoic acid (Δ2(E)-valproate) was administered to healthy volunteers in oral doses of 50–800 mg. The drug was tolerated well and no significant adverse effects were observed. Pharmacokinetic parameters were determined. Valproate and 3-keto-valproate were detected as metabolites.

Keywords

Drug evaluation Pharmacokinetics 2-n-Propyl-2(E)-pentenoic acid Side effects Valproic acid 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gram L, Bentsen KD. Valproate. An updated review. Acta Neurol Scand 1985;72:129–39.PubMedGoogle Scholar
  2. 2.
    Schmidt D. Behandlung der Epilepsien. 2nd ed. Stuttgart: Georg Thieme Verlag, 1984:169–71.Google Scholar
  3. 3.
    Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities. A retrospective review. Neurology 1987;37:379–85.PubMedGoogle Scholar
  4. 4.
    Scheffner D, König S, Rauterberg-Ruland I, Kochen W, Hofmann WJ, Unkelbach S. Fatal liver failure in 16 children with valproate therapy. Epilepsia 1988;29:530–42.PubMedGoogle Scholar
  5. 5.
    Gross-Selbeck G. Valproat — ein risikoreiches Medikament? Epilepsie-Blatt 1988;1(1).Google Scholar
  6. 6.
    Dreifuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid hepatic fatalities. II. US experience since 1984. Neurology 1989;39:201–7.PubMedGoogle Scholar
  7. 7.
    Gomez MR. Possible teratogenicity of valproic acid. J Pediatr 1981;98:508–9.PubMedGoogle Scholar
  8. 8.
    Jäger-Roman E, Deichel A, Jakob S, Hartmann A-M, Koch S, Rating D, et al. Fetal growth, major malformations and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986;108: 997–1004.PubMedGoogle Scholar
  9. 9.
    DiLiberti JH, Farndon PA, Dennis NR, Curry CJR. The fetal valproate syndrome. Am J Med Gen 1984;19: 473–81.CrossRefPubMedGoogle Scholar
  10. 10.
    Lammer EJ, Sever LE, Oakley GP. Teratogen update. Valproic acid. Teratology 1987;35:465–73.CrossRefPubMedGoogle Scholar
  11. 11.
    Ardinger HH, Arkin JF, Blackstone RD, Elsas LJ, Clarren SK, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Gen 1988;29:171–85.CrossRefPubMedGoogle Scholar
  12. 12.
    Nau H, Zierer R, Gansau C, Neubert D, Spielmann H. A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations. Life Sci 1981;29:2803–14.CrossRefPubMedGoogle Scholar
  13. 13.
    Kuhara T, Hirohata Y, Yamada S, Matsumoto I. Metabolism of sodium dipropylacetate in humans. Eur J Drug Metab Pharmacokinet 1978;3:171–7.Google Scholar
  14. 14.
    Taillandier G, Benot-Guyot J-L, Boucherle A, Broll M, Eymard P. Recherches dans la série dipropylacétique XII. Acides et alcools aliphatiques ramifiés anticonvulsivants. Eur J Med Chem Chim Ther 1975;10:453–62.Google Scholar
  15. 15.
    Löscher W.Trans-2-en-valproic acid. Drugs Future 1985;(10):389–91.Google Scholar
  16. 16.
    Löscher W, Nau H, Marescaux C, Vergnes M. Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy. Eur J Pharmacol 1984;99:211–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Löscher W, Böhme G, Schäfer H, Kochen W. Effect of metabolites of valproic acid on the metabolism of GABA in brain nerve endings. Neuropharmacology 1981;20:1187–92.CrossRefPubMedGoogle Scholar
  18. 18.
    Keane PE, Simiand J, Morre M. Comparison of the pharmacological and biochemical profiles of valproic acid (VPA) and its cerebral metabolite (2-en-VPA) after oral administration in mice. Meth Find Exp Clin Pharmacol 1985;7(2):83–6.Google Scholar
  19. 19.
    Anticonvulsant activity in rodents [internal report no: RS 300900 214/MC 2]. Montpellier: Sanofi, 1989.Google Scholar
  20. 20.
    Nau H, Wittfoht W, Schäfer H, Jacobs C, Rating D, Helge H. Pharmacokinetics of valproic acid and metabolites in mouse plasma and brain following constantrate application of the drug and its unsaturated metabolite with an osmotic delivery system. J Chromatogr 1981;226:69.PubMedGoogle Scholar
  21. 21.
    Dreifuss FE, Langer DH. Side effects of valproate. Am J Med 1988;84 Suppl 1A:39–41.CrossRefPubMedGoogle Scholar
  22. 22.
    Wilder BJ, Ramsay RE, Murphy JV, Karas BJ, Marquardt K, Hammond EJ. Comparison of valproic acid and phenytoin in newly diagnosed tonic-clonic seizures. Neurology 1983;33:1474–6.PubMedGoogle Scholar
  23. 23.
    Levy RH, Shen DD. Valproate. Absorption, distribution, and excretion. In: Levy R, Mattson R, Meldrum B, Penry JK, Dreifuss FE. Antiepileptic drugs. 3rd ed. New York: Raven Press, 1989.Google Scholar
  24. 24.
    Schulz HU, Lührmann B, Kraus G. Single dose bioavailability study of controlled release valproate: Orfiril® retard enteric coated tabletsvs Orfiril® enteric coated tablets [internal report, no: VPA-001]. Hamburg: Desitin Arzneimittel, 1990.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1992

Authors and Affiliations

  • R. H. Düsing
    • 1
  1. 1.Desitin ArzneimittelHamburg 63Germany

Personalised recommendations